David Nierengarten


Juno Therapeutics Inc (JUNO) Looks Well Positioned in Light of KITE Takeout: Top Analyst

David Nierengarten Re-evaluates JUNO; Upgrades Shares to Outperform

Wedbush Top Analyst Lifts Price Target on Kite Pharma Inc (KITE), But Remains on the Sidelines

Following a KOL discussion of Car-T therapies coupled with this week’s encouraging clinical update on the ZUMA-1 trial in Non-Hodgkin’s lymphoma (LMA), top …

Wedbush Top Analyst Downgrades and Chops Price Target on Novan Inc (NOVN); Phase 3 Miss Places Entire SB204 Program in Jeopardy

Novan Inc (NASDAQ:NOVN) stock torpedoed on Friday after the biotech firm’s lead pipeline drug for the treatment of acne vulgaris failed its Phase …

This Top Analyst Bullish on bluebird bio Inc (BLUE) Following R&D Day

On October 13th, bluebird bio Inc (NASDAQ:BLUE) hosted a Research and Development (R&D) Day shining light on its newly implemented process and manufacturing …

Wedbush Top Analyst Remains Sidelined on MEI Pharma Inc (MEIP) Despite Receiving Breakthrough Therapy Designation; Here’s Why

MEI Pharma Inc (NASDAQ:MEIP) just received Breakthrough Therapy Designation for its key pipeline drug pracinostat, anti-tumor molecule inhibitor that combined with azacitidine treats …

Wedbush Doubles Price Target For Anacor Pharmaceuticals Inc; Here’s Why

Anacor Pharmaceuticals Inc (NASDAQ:ANAC) shares jumped nearly 56% today after the company announced preliminary positive top-line results from its two Phase 3 pivotal studies of …

Wedbush Remains Sidelined on Sunesis Pharmaceuticals, Inc. Following VALOR Phase 3 Trial Update

In a research report published Friday, Wedbush analyst David Nierengarten maintained a Neutral rating on Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) with a $2.

Wedbush Keeps MEI Pharma Inc at Neutral Following Updated Pracinostat Phase 2 Data

In a research report released Friday, Wedbush analyst David Nierengarten reiterated a Neutral rating on MEI Pharma Inc (NASDAQ:MEIP) with a $3 price target, …

Wedbush Reiterates Neutral On NPS Pharmaceuticals Despite FDA Approval For Natpara

Wedbush analyst David Nierengarten was out with some neutral comments on NPS Pharmaceuticals (NASDAQ:NPSP), following the news that the company’s Natpara has been approved by the FDA to …

Wedbush Reiterates Outperform On Bluebird Bio Following LentiGlobin Data Release

In a research report released yesterday, Wedbush analyst David Nierengarten reiterated an Outperform rating on Bluebird Bio (NASDAQ:BLUE) with a price target of …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts